Media.Player

Use Of Antibiotic Peptides Produced By Human Corneal Epithelial Cells To Manage Infection

Technology Benefits

Use of human recombinant peptide would minimize allergic reactions. By enhancing the killing and removal of bacterial pathogens from the eye, the antibacterial peptide or compounds that induceits expression would promote healing of ocular tissues damaged by the bacterial disease process.

Technology Application

Topical application of the antibacterial peptide itself to human ocular tissues to treat an infection of the cornea, conjunctiva, or adnexa caused bysusceptible bacterial pathogTopical application of the antibacterial peptide, in combination with existing topical ocular antibacterial drugs, to the human eye to treat activeinfections of the cornea, conjunctiva, or adnexa caused by susceptible bacteria. Combination therapy minimizes resistance, and the peptide is likelyto be additive or even synergistic with aminoglycoside or Fluoroquinolone ocular antibacterial drugs.Topical application of a compound that induces increased expression of the antibacterial peptide in human ocular tissues to treat an activeinfection of the cornea, conjunctiva, or adnexa caused by susceptible bacterial pathogens. This approach causes the eye to use its own defensesystem. Bacterial resistance to the inducing compound would be unlikely since the inducer would not itself be antibacterial. Topical application of the antibacterial peptide and/or an inducer of the antibacterial peptide prophylactically, to human ocular tissues to preventan active infection of the cornea, conjunctiva, or lids in an individual deemed at risk of developing such an infection.

Detailed Technology Description

None

Supplementary Information

Patent Number: US6984622B2
Application Number: US2002121227A
Inventor: Fleiszig, Suzanne M. J. | McNamara, Nancy A.
Priority Date: 25 Mar 1998
Priority Number: US6984622B2
Application Date: 10 Apr 2002
Publication Date: 10 Jan 2006
IPC Current: A61K003800 | A61K003817 | G01N003368
US Class: 5140021 | 514002 | 5140094 | 5140208 | 514012
Assignee Applicant: The Regents of the University of California
Title: Use of lipopolysaccharides to manage corneal infections and wounds
Usefulness: Use of lipopolysaccharides to manage corneal infections and wounds
Summary: The antibiotic polypeptide hBD-2 is useful for preventing or treating cutaneous wounds affecting the epidermal and dermal layers of the skin, or ocular wounds, such as corneal wound or corneal infection caused by Pseudomonas aeruginosa or other pathogens. The hBD-2-stimulating compound is useful for upregulating the endogenous expression of hBD-2. The hBD-2 can be used as tear film supplements used in conjunction with contact lens wear preventing bacterial infection. The β-defensins can also be used as a component in the solutions used for storage and transfer of corneas prior to transplant.
Novelty: Use of a human beta defensin-2 polypeptide for preventing or treating cutaneous wounds or ocular wounds, such as corneal wound or corneal infection commonly caused by Pseudomonas aeruginosa

Industry

Disease Diagnostic/Treatment

Sub Category

Other Disease

Others

Tech ID/UC Case

18550/1998-040-0

Related Cases

1998-040-0

*Abstract

UC Berkeley researchers have discovered an antibacterial peptide produced by human ocular tissues. This peptide is part of the ocular defense against infection, and is active against a wide range of ocular disease-causing bacteria. In addition to discovery of the antibacterial peptide itself, Berkeley researchers have identified pathways by which expression of this antibacterial compound in the eye may be upregulated (increased) when needed to combat an infecting bacterial pathogen. Applications of this technology include:

*Principal Investigator

Name: Suzanne Fleiszig

Department:

Name: NANCY MCNAMARA

Department:

Country/Region

USA